

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

SW620

RRID:CVCL_0547

Type: Cell Line

Proper Citation

RRID:CVCL_0547

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0547

Proper Citation: RRID:CVCL_0547

Description: Cell line SW620 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:286328](#), [PMID:288927](#), [PMID:327080](#), [PMID:833871](#), [PMID:924690](#), [PMID:1000501](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6582512](#), [PMID:7972006](#), [PMID:9023415](#), [PMID:9178645](#), [PMID:9290701](#), [PMID:9294210](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:10773689](#), [PMID:11113861](#), [PMID:11226274](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:12068308](#), [PMID:12107847](#), [PMID:15748285](#), [PMID:16854228](#), [PMID:17088437](#), [PMID:18258742](#), [PMID:19188929](#), [PMID:19372543](#), [PMID:19927377](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23272949](#), [PMID:23631600](#), [PMID:23856246](#), [PMID:23932154](#), [PMID:23933261](#), [PMID:24042735](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24755471](#), [PMID:24840470](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27470641](#), [PMID:27807467](#), [PMID:27987026](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29131639](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32172478](#), [PMID:35839778](#), [PMID:36648961](#), [PMID:38861359](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL)

panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW620

Synonyms: SW-620, SW_620, SW 620, SW.620

Cross References: BTO:BTO_0000675, CLO:CLO_0009196, CLO:CLO_0009221, EFO:EFO_0002368, MCCL:MCC:0000448, CLDB:cl4443, CLDB:cl4444, CLDB:cl4969, AddexBio:C0009002/68, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-227, BCRC:60343, BioGRID_ORCS_Cell_line:361, BioSample:SAMN03481108, BioSample:SAMN05292430, BioSample:SAMN07709977, BioSample:SAMN07709978, BioSample:SAMN07709979, BioSample:SAMN07709980, BioSample:SAMN07709981, BioSample:SAMN07709982, BioSample:SAMN07709983, BioSample:SAMN10988250, cancercellines:CVCL_0547, CCRID:1101HUM-PUMC000207, CCRID:3101HUMTCHu101, Cell_Model_Passport:SIDM00841, ChEMBL-Cells:ChEMBL3307944, ChEMBL-Targets:ChEMBL612262, CLS:300466, ColonAtlas:SW620, Cosmic:719676, Cosmic:724849, Cosmic:873706, Cosmic:875294, Cosmic:875900, Cosmic:876720, Cosmic:887243, Cosmic:889525, Cosmic:897460, Cosmic:905962, Cosmic:934561, Cosmic:948828, Cosmic:974248, Cosmic:983733, Cosmic:986020, Cosmic:990304, Cosmic:1071889, Cosmic:1092640, Cosmic:1122333, Cosmic:1154646, Cosmic:1175845, Cosmic:1176590, Cosmic:1183768, Cosmic:1184083, Cosmic:1187324, Cosmic:1219446, Cosmic:1223150, Cosmic:1305357, Cosmic:1310936, Cosmic:1312341, Cosmic:1466823, Cosmic:1479589, Cosmic:1524325, Cosmic:1552181, Cosmic:1609505, Cosmic:1676751, Cosmic:1708397, Cosmic:1995654, Cosmic:1998483, Cosmic:2156943, Cosmic:2302019, Cosmic:2389570, Cosmic:2668250, Cosmic:2727483, Cosmic:2760070, Cosmic:2823493, Cosmic-CLP:905962, DepMap:ACH-000651, ECACC:87051203, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905962, GEO:GSM2107, GEO:GSM50192, GEO:GSM50256, GEO:GSM206553, GEO:GSM274773, GEO:GSM274774, GEO:GSM513819, GEO:GSM513867, GEO:GSM514313, GEO:GSM514314, GEO:GSM741270, GEO:GSM743447, GEO:GSM750800, GEO:GSM784023, GEO:GSM799335, GEO:GSM799398, GEO:GSM847163, GEO:GSM887677, GEO:GSM888769, GEO:GSM1006236, GEO:GSM1006237, GEO:GSM1006238, GEO:GSM1153405, GEO:GSM1178644, GEO:GSM1178645, GEO:GSM1178646, GEO:GSM1181305, GEO:GSM1181343, GEO:GSM1346892, GEO:GSM1374933, GEO:GSM1374934, GEO:GSM1374935, GEO:GSM1448212, GEO:GSM1862127, GEO:GSM1862128, GEO:GSM1862129, GEO:GSM2124652, GEO:GSM2299789, GEO:GSM2550017, GEO:GSM3591769, IARC_TP53:20, ICLC:HTL99015, IGRhCellID:SW620, KCB:KCB 2011098YJ, KCLB:10227, KCLB:60068, LiGeA:CCLE_536, LINCS_HMS:50047, LINCS_LDP:LCL-1157, Lonza:543, MetaboLights:MTBLS227, NCI-DTP:SW-620, PharmacDB:SW620_1541_2019, PRIDE:PXD000089, PRIDE:PXD003539, PRIDE:PXD003708, PRIDE:PXD004079, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD006662, PRIDE:PXD030304, PRIDE:PXD037651, Progenetix:CVCL_0547, PubChem_Cell_line:CVCL_0547, SKY/M-FISH/CGH:2806, SKY/M-FISH/CGH:5075, Wikidata:Q28519412

ID: CVCL_0547

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260830T000042+0000

Ratings and Alerts

No rating or validation information has been found for SW620.

No alerts have been found for SW620.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 1616 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Y, et al. (2026) Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. *Biochemical pharmacology*, 249, 117904.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Koo TY, et al. (2026) Protocol to identify covalent inhibitors targeting RhoA Cys16. *STAR protocols*, 7(2), 104494.

Liu X, et al. (2026) Role of Ca²⁺-Dependent Epithelial-Mesenchymal Transition in Malignant Progression of Colorectal Cancer: Special Focus on REG I^{??}/EDNRB. *Cancer medicine*, 15(4), e71754.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.

Radloff HS, et al. (2026) A single-cell derived spheroid approach to dissect intratumoural heterogeneity in colorectal cancer: cell lines show changes in proteomes and therapeutic response to 5-FU. *Journal of cancer research and clinical oncology*, 152(1), 43.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Beardsley JM, et al. (2026) Colorectal cancer-derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver. *Molecular oncology*, 20(6), 1494.

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16557.

Qing S, et al. (2026) Folate promotes colorectal cancer progression by impairing CD8+ T cell function and recruitment via SLC19A1/p-AKT/NOTCH1 axis and CCL5 downregulation. *Journal of translational medicine*, 24(1).

Veltsista PD, et al. (2026) Non-Temperature-Induced Antitumor Effects of Amplitude-Modulated Radiofrequency: Molecular and Functional Synergies with Radiotherapy. *Cancers*, 18(10).

Menadi S, et al. (2026) Synergistic Anticancer Effects of *Akkermansia muciniphila* Combined With 5-Fluorouracil Through BAX/BCL2 Dependent Apoptosis in Colorectal Cancer Cells. *Cell biochemistry and function*, 44(5), e70234.

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Jin S, et al. (2026) IFITM1-targeted NIR-II fluorescence imaging enables visualisation of colorectal cancer and metastatic lymph nodes. *Journal of translational medicine*, 24(1).

Li Z, et al. (2026) Engineered pistol ribozymes selectively target KRAS G12V with enhanced efficacy by capping modification. *Cell chemical biology*, 33(5), 671.

Hmone NY, et al. (2026) Discovery of novel coumarin-containing triazolo[1,5-a]pyrimidine derivatives as potent ABCB1 inhibitor for modulation of multidrug resistance. *Journal of enzyme inhibition and medicinal chemistry*, 41(1), 2629074.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

Gao J, et al. (2026) AURKA-mediated destabilization of SAPS3 drives ferroptosis evasion via 7-dehydrocholesterol biosynthesis in colorectal cancer. *Cell death & disease*, 17(1).

Chen K, et al. (2026) Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models. *Science translational medicine*, 18(840), eadx4097.